Marc A Rodger1, Dimitri Scarvelis2, Susan R Kahn3, Philip S Wells2, David A Anderson4, Isabelle Chagnon5, Grégoire Le Gal2, Esteban Gandara2, Susan Solymoss6, Elham Sabri2, Judy Kovacs7, Michael J Kovacs8. 1. Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Health Research Institute, The Ottawa Hospital, Ottawa, Ottawa, Ontario, Canada. Electronic address: mrodger@ohri.ca. 2. Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, Ottawa Health Research Institute, The Ottawa Hospital, Ottawa, Ottawa, Ontario, Canada. 3. Department of Medicine, McGill University, Montreal, Canada; Centre for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, Canada. 4. Department of Medicine, Dalhousie University, Halifax, Nova Scotia. 5. Department of Medicine, Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, Canada. 6. Department of Medicine, McGill University, Montreal, Canada. 7. London Health Sciences Center, London, Ontario, Canada. 8. Division of Hematology, Department of Medicine, University of Western Ontario, London, Ontario, Canada.
Abstract
BACKGROUND: Choosing short-term (3-6 months) or indefinite anticoagulation after a first unprovoked venous thromboembolic event (VTE) is a common and difficult clinical decision. The long-term absolute risk of recurrent VTE after a first unprovoked VTE, in all patients and sub-groups, is not well established, hindering decision making. METHODS: We conducted a multi-center multi-national prospective cohort study in first unprovoked VTE patients to establish the long-term risk of recurrent VTE after short-term anticoagulation in first unprovoked VTE patients (and sub-groups).We followed patients for symptomatic suspected VTE off of OAT. Suspected recurrent VTE was investigated with reference to baseline imaging and then independently and blindly adjudicated. FINDINGS: We recruited 663 participants between October, 2001 and March 2006 with the last follow-up in April 2014. During a mean 5.0 years of follow-up, 165/663 suspected VTE (in 408 patients) were adjudicated as recurrent VTE resulting in an annualized risk of recurrent VTE of 5.0% (95% CI: 4.2-5.8%) with a cumulative risk of 29.6% at 8 years. Men had a 7.6% (95% CI: 6.3-9.2%) annual risk of recurrent VTE. High risk women (2 or more HERDOO2 points; see text) had an annual risk of recurrent VTE of 5.9% (95% CI: 4.2-8.1%). Low risk women (1 or 0 HERDOO2 points) had 1.1% (95% CI: 0.6-2.0%) annual risk of recurrent VTE with a cumulative risk of 8.7% at 8 years. INTERPRETATION: Men and high risk women with unprovoked VTE should be considered for long-term anticoagulant therapy given a high risk of recurrent VTE after long-term follow-up. Women with a low HERDOO2 score may be able to safely discontinue anticoagulants. FUNDING: This study was funded by the Canadian Institutes of Health Research (Grant # MOP 64319) and Heart and Stroke Foundation of Ontario (Grant # NA 6771). Registered at www.clinicaltrials.gov identifier: NCT00261014.
BACKGROUND: Choosing short-term (3-6 months) or indefinite anticoagulation after a first unprovoked venous thromboembolic event (VTE) is a common and difficult clinical decision. The long-term absolute risk of recurrent VTE after a first unprovoked VTE, in all patients and sub-groups, is not well established, hindering decision making. METHODS: We conducted a multi-center multi-national prospective cohort study in first unprovoked VTEpatients to establish the long-term risk of recurrent VTE after short-term anticoagulation in first unprovoked VTEpatients (and sub-groups).We followed patients for symptomatic suspected VTE off of OAT. Suspected recurrent VTE was investigated with reference to baseline imaging and then independently and blindly adjudicated. FINDINGS: We recruited 663 participants between October, 2001 and March 2006 with the last follow-up in April 2014. During a mean 5.0 years of follow-up, 165/663 suspected VTE (in 408 patients) were adjudicated as recurrent VTE resulting in an annualized risk of recurrent VTE of 5.0% (95% CI: 4.2-5.8%) with a cumulative risk of 29.6% at 8 years. Men had a 7.6% (95% CI: 6.3-9.2%) annual risk of recurrent VTE. High risk women (2 or more HERDOO2 points; see text) had an annual risk of recurrent VTE of 5.9% (95% CI: 4.2-8.1%). Low risk women (1 or 0 HERDOO2 points) had 1.1% (95% CI: 0.6-2.0%) annual risk of recurrent VTE with a cumulative risk of 8.7% at 8 years. INTERPRETATION:Men and high risk women with unprovoked VTE should be considered for long-term anticoagulant therapy given a high risk of recurrent VTE after long-term follow-up. Women with a low HERDOO2 score may be able to safely discontinue anticoagulants. FUNDING: This study was funded by the Canadian Institutes of Health Research (Grant # MOP 64319) and Heart and Stroke Foundation of Ontario (Grant # NA 6771). Registered at www.clinicaltrials.gov identifier: NCT00261014.
Authors: Alana Nevares; Kinanah Yaseen; Hiromichi Tamaki; James Bena; William Messner; Alexandra Villa-Forte Journal: Rheumatol Adv Pract Date: 2022-07-01
Authors: Faizan Khan; Alvi Rahman; Marc Carrier; Clive Kearon; Sam Schulman; Francis Couturaud; Paolo Prandoni; Sabine Eichinger; Cecilia Becattini; Giancarlo Agnelli; Harry R Büller; Timothy A Brighton; Gualtiero Palareti; Laurent Pinede; Elham Sabri; Brian Hutton; George A Wells; Marc A Rodger Journal: BMJ Open Date: 2017-09-21 Impact factor: 2.692
Authors: Sara Reda; Elena Thiele Serra; Jens Müller; Nasim Shahidi Hamedani; Johannes Oldenburg; Bernd Pötzsch; Heiko Rühl Journal: Front Cardiovasc Med Date: 2022-03-31